We would like to thank Dr Krishnan and colleagues for their interest in our work. They have raised additional limitations of our work and question whether platelets express myeloid-related protein-14 (MRP-14). Their caution is reasonable. However, we have provided additional evidence that MRP-14 is expressed in bone marrow-derived human megakaryocytes and megakaryocytes differentiated in vitro from CD34-positive peripheral blood cells (Data Supplement Figure I of our article 1 ). We also have detected MRP-8/14 protein in human platelets by flow cytometry (data not shown). Double antibody experiments show costaining for the platelet-specific marker glycoprotein IIb/IIIa and for MRP-8/ 14. MRP-8/14 -positive platelets were negative for the leukocyte marker CD45, ruling out leukocyte contamination as a source of the MRP-8/14 signal.
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